Merck Hedges Bets With Keytruda Lung Study

Merck has started a big study testing whether its immunotherapy drug, Keytruda, helps newly diagnosed lung cancer patients more if it is combined with Yervoy, a drug made by rival Bristol-Myers Squibb. But don ' t interpret the study as a bet the combination will prove effective.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news